跳至主要内容
临床试验/NCT04907877
NCT04907877已完成不适用

Role of Nutritional Support With Probiotics in Adult Outpatients With Symptomatic COVID-19: a Randomized Dietary Study

Nordic Biotic Sp. z o.o.6 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
70
试验地点
6
主要终点
Global symptom score

研究概览

简要总结

There is evidence that some types of probiotics play a role in alleviation of symptoms of acute respiratory tract infections and bursting immune response to respiratory and enteric viruses. Available data serves a rationale for the study exploring a role of nutritional support with probiotics in adult outpatients with COVID-19. Hypothesis of the study is that a proposed mixture of lactobacilli and bifidobacteria facilitate faster recovery from COVID-19 and enhance specific immune response to SARS-CoV-2 antigens.

详细描述

One hundred adults with confirmed (PCR or antigen test) symptomatic COVID-19 lasting upto 5 days will be screened for the study. When the subject meets enrollment criteria, he/she will be randomized to take an investigational product (probiotic, test dietary supplement, TDS), a mixture of lactobacilli and bifidobacteria or placebo 1 time a day before breakfast for 28 days after enrollment. During observation, the patient will keep Respiratory Illness Diary. Blood serum will be collected at baseline, day 0-5 (Nurse Visit 1), after 28-35 days (Nurse visit 2), and 6 months (Nurse visit 3) for evaluation of anti-SARS-CoV-2 antibodies to nucleocapsid and spike antigents. In 3 months, investigator/family physician will collect Post-COVID-19 Questionnaire

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 - ≤ 65 years;
  • Male or non-pregnant female;
  • Informed virtual pre-consent and paper signed consent forms;
  • Confirmed symptomatic COVID-19 lasting 0-5 days;
  • Subject understands and agrees to comply with study procedures including triple blood analysis for anti-SARS-CoV-2 IgG;

排除标准

  • Risk for the complicated course of COVID-19 due to:
  • Hypertension; 1.
  • Diabetes mellitus; 1.
  • Immunosuppressive conditions; 1.
  • Chronic pathology of the respiratory system ; 1.
  • Chronic pathology of the cardiovascular system ; 1.
  • Malignant tumor ; 1.
  • Systemic inflammatory connective tissue disease ; 1.
  • Cerebrovascular disease ; 1.
  • Chronic hepatitis. Hepatic cirrhosis; 1.
  • Inflammatory bowel diseases ; 1.
  • Chronic kidney disease ;
  • Drug or alcohol abuse as suspected by investigator;
  • History of persistent diarrhea of any cause;
  • Use of pre- or probiotics during the last 2 weeks before enrollment;
  • Allergy to any components of the TDS;
  • Technical difficulties to perform virtual study visits.
  • Inability to perform a blood test for antibodies after 6 months
  • Inability to swallow capsules, or choking / coughing while eating

结局指标

主要结局

Global symptom score

时间窗: 10 days

Clinical score of Coronavirus disease-19; minimal score 0 (healthy), maximal score 36 (worst disease)

次要结局

  • Hospitalization rate(28 days)
  • 8 - point ordinal severity scale of coronavirus disease-19(28 days)
  • Time to recovery(28 days)
  • Percent of completely recovered patients(28 days)

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Sergei Gerasymov, MD, PhD

Principal Investigator

Nordic Biotic Sp. z o.o.

研究点 (6)

Loading locations...

相似试验